AlphAIalphai — Financial news for AI agents
tickerreport.comJUN 23 min read$RDVT

Red Violet (NASDAQ:RDVT) Insider Jeffrey Alan Dell Sells 10,000 Shares

Red Violet (NASDAQ:RDVT) insider Jeffrey Alan Dell sold 10,000 shares on June 1 at an average $57.44, totaling $574,400, according to an SEC filing. After the sale, he directly owned 155,889 shares (~$8.95M). The stock traded around $59.30 midday. In its May 6 quarter, RDVT reported $0.46 EPS and $25.83M revenue.

Original reporting
tickerreport.com
Published Jun 2, 2026, 1:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:19 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Red Violet (NASDAQ:RDVT) Insider Jeffrey Alan Dell Sells 10,000 Shares — source image
Source · tickerreport.com
Decision brief

The 30-second read

$RDVTNeutralLow
01

Why it matters

This is primarily a sentiment/positioning datapoint. Without new guidance, contract, or regulatory developments, it is unlikely to materially reprice the company by itself.

02

Market read

Traders may monitor RDVT for follow-through in sentiment, but the actionable driver remains the company’s recent earnings/analyst stance rather than this transaction alone.

03

What to watch

The piece also notes recent earnings beat and multiple analyst downgrades to Hold; traders may weigh those fundamentals more than the single insider sale.

Relevance 6/10Novelty 6/10Timing: Today/this week: SEC Form 4 insider sale disclosed for June 1 transaction.

Background

The article is an SEC-disclosed insider transaction (Form 4) tied to Red Violet’s stock performance and recent earnings/analyst commentary.

Company-level read

Ticker impact

$RDVTNeutralMedium confidence
Context

Red Violet insider Jeffrey Alan Dell sold 10,000 shares at an average $57.44, reducing his stake by 6.03% per SEC filing.

Expected impact

Likely limited/short-lived impact; any move would be dominated by broader earnings/analyst sentiment rather than this single sale.

Evidence & confidence

The disclosure is time-stamped (June 1 sale) and ownership decreased, but there is no accompanying guidance change, deal, or regulatory event.

Market effects

Sector

Minor read-through for fintech/financial-crime analytics names: insider selling can modestly affect sentiment around governance/valuation, but no sector-wide shock is indicated.

Regional

Primarily US small/mid-cap sentiment; no cross-region linkage described.

Global

Limited global relevance; the event is company-specific insider activity.

Counterpoint

What could challenge this read

Insider sales can be routine (taxes/diversification) and may not reflect negative expectations; the article doesn’t state motive or whether it was pre-planned under a trading plan.

Key entities

  • company
    Red Violet, Inc.

    NASDAQ-listed provider of data/analytics solutions for financial crime, fraud and security risk; subject of the insider sale disclosure.

  • insider
    Jeffrey Alan Dell

    Insider who sold 10,000 RDVT shares at $57.44 average price on June 1, reducing ownership by 6.03%.

Read at source← All news

Related articles

AUG 11
$RDVTMed

Red Violet, Inc. (RDVT): Results of Operations and Financial Condition

Red Violet, Inc. (RDVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 red violet Reports Second Quarter 2026 Financial Results Record Revenue of $26.7 Million, an Increase of 23%; Record Cash Flow from Operations of $10.6 Million BOCA RATON, Fla. – August 10, 2026 – Red Violet, Inc. (NASDAQ: RDVT), a leading identity intelligence and a

SEC EDGAR 8-K4 min
AUG 7
$RDVTMedAI 8/10

red violet Announces Closing of $115 Million Underwritten Public Offering of Common Stock, Including Full Exercise of Underwriters' Option

Red Violet, Inc. (NASDAQ: RDVT) said it closed an underwritten public offering of 1,916,667 shares of common stock, including 250,000 shares from full exercise of the underwriters’ option. The company estimates net proceeds of about $108.6 million. Proceeds will be used for working capital, general corporate purposes, and potential strategic acquisitions.

itnewsonline.com2 min
AUG 6
$RDVTMedAI 8/10

red violet Announces Pricing of $100 Million Underwritten Public Offering of Common Stock

Red Violet, Inc. (NASDAQ: RDVT) priced an underwritten public offering of 1,666,667 shares of common stock at $60.00 per share, raising expected gross proceeds of $100 million before underwriting fees and expenses. The offering is expected to close Aug. 7, 2026, with a 30-day option for up to 250,000 additional shares. Net proceeds will fund working capital and corporate purposes.

itnewsonline.com2 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min